NCT04463615View on ClinicalTrials.gov

Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

July 28, 2021

Study Completion Date

July 28, 2021

Conditions
Recurrent Lymphoproliferative DisorderRefractory Lymphoproliferative Disorder
Interventions
DRUG

Leflunomide

Given PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER